VIRGINIA RETIREMENT SYSTEMS ET Al Has $2.38 Million Stake in Jazz Pharmaceuticals PLC $JAZZ

VIRGINIA RETIREMENT SYSTEMS ET Al decreased its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 41.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 13,970 shares of the specialty pharmaceutical company’s stock after selling 9,730 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Jazz Pharmaceuticals were worth $2,375,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vestal Point Capital LP purchased a new stake in Jazz Pharmaceuticals in the 2nd quarter worth approximately $127,344,000. Goldentree Asset Management LP purchased a new stake in Jazz Pharmaceuticals in the 3rd quarter worth approximately $149,597,000. Schonfeld Strategic Advisors LLC lifted its position in Jazz Pharmaceuticals by 592.1% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 436,443 shares of the specialty pharmaceutical company’s stock worth $57,523,000 after buying an additional 373,383 shares in the last quarter. AQR Capital Management LLC lifted its position in Jazz Pharmaceuticals by 62.1% in the 2nd quarter. AQR Capital Management LLC now owns 794,770 shares of the specialty pharmaceutical company’s stock worth $84,341,000 after buying an additional 304,463 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in Jazz Pharmaceuticals by 11.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company’s stock worth $373,855,000 after buying an additional 298,815 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on JAZZ shares. Truist Financial upgraded shares of Jazz Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, March 25th. Barclays increased their target price on shares of Jazz Pharmaceuticals from $225.00 to $234.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Leerink Partners raised their price target on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a report on Wednesday, April 22nd. Robert W. Baird set a $252.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, May 6th. Finally, Morgan Stanley restated an “overweight” rating and set a $245.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $230.56.

Insider Transactions at Jazz Pharmaceuticals

In related news, CAO Patricia Carr sold 1,287 shares of Jazz Pharmaceuticals stock in a transaction on Monday, March 9th. The shares were sold at an average price of $182.94, for a total value of $235,443.78. Following the transaction, the chief accounting officer owned 6,512 shares in the company, valued at $1,191,305.28. This trade represents a 16.50% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Neena M. Patil sold 55,600 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $191.56, for a total transaction of $10,650,736.00. Following the completion of the transaction, the executive vice president owned 56,862 shares in the company, valued at $10,892,484.72. This trade represents a 49.44% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 74,015 shares of company stock worth $14,180,486. Corporate insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Stock Down 1.0%

Jazz Pharmaceuticals stock opened at $228.77 on Friday. The company has a market capitalization of $14.35 billion, a P/E ratio of -11,432.78, a P/E/G ratio of 0.41 and a beta of 0.27. The firm’s fifty day simple moving average is $197.18 and its 200-day simple moving average is $176.51. The company has a current ratio of 2.04, a quick ratio of 1.85 and a debt-to-equity ratio of 0.95. Jazz Pharmaceuticals PLC has a 1-year low of $105.00 and a 1-year high of $235.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. The business had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. Sell-side analysts forecast that Jazz Pharmaceuticals PLC will post 20.75 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.